Skip to main content

Table 3 Comparison of flare and non-flare group in SACQ and SQCQ

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

 

SACQ (170)

SQCQ (187)

Flare (56)

Non-flare (114)

p

Flare (29)

Non-flare (158)

p

Age at diagnosis (years)

30.95 ± 13.88

32.65 ± 14.61

0.469

34.19 ± 14.14

39.42 ± 15.15

0.086

Gender (male to female)

8:48

13:101

0.624

2:27

17:141

0.765

Recurrence time or follow-up timea (months)

21.82 (13.39, 31.59)

19.23 (10.02, 34.32)

0.440

26.43 (16.72, 41.97)

22.92 (11.63, 43.65)

0.361

Duration of serological activity/inactivity before SACQ/SQCQ (months)

13.58 (6.94, 25.19)

15.49 (7.31, 25.87)

0.771

11.10 (5.77, 21.72)

8.88 (3.01, 15.99)

0.115

Time to SACQ/SQCQb (months)

23.88 (13.03, 50.68)

22.07 (12.16, 50.62)

0.562

21.0 (11.85, 58.65)

17.28 (9.84, 36.53)

0.241

Dose of corticosteroids at the start of SACQ/SQCQ

7.5 (5.0, 7.5)

7.5 (6.25, 7.5)

0.096

7.5 (5.0, 7.5)

7.5 (5.0, 7.5)

0.608

Taking antimalarials at the start of SACQ/SQCQ

40/56 (71.4%)

90/114 (78.9%)

0.277

22/29

132/158

0.319

Taking immunosuppressants at the start of SACQ/SQCQ

29/56 (51.8%)

67/114 (58.8%)

0.414

15/29

84/158

0.886

Dose of corticosteroidsc (mg) when relapsed or at the end of follow-up

5.0 (2.81,7.5)

3.75 (1.25, 5.0)

0.011

5.0 (0, 5.0)

3.75 (1.25, 5.0)

0.489

Taking antimalarials when relapsed or at the end of follow-up

36/56 (64.3%)

97/114 (85.1%)

0.002

17/29 (58.6%)

135/158 (85.4%)

0.001

Taking immunosuppressants when relapsed or at the end of follow-up

23/56 (41.1%)

69/114 (60.5%)

0.017

10/29 (34.5%)

87/158 (55.1%)

0.041

Anti-dsDNA (+)

41/56 (73.2%)

96/114 (84.2%)

0.101

Hypocomplementemia

26/56 (46.4%)

36/114 (31.6%)

0.064

Symptoms at initial diagnosis.

 LN

16/56 (28.6%)

46/114 (40.4%)

0.175

10/29 (34.5%)

58/158 (36.7%)

0.819

 NPSLE

2/56 (3.6%)

6/114 (5.3%)

1.000

1/29 (3.4%)

10/158 (6.3%)

0.860

 Thrombocytopenia

9/56 (16.1%)

14/114 (12.3%)

0.485

6/29 (20.7%)

30/158 (19.0%)

0.831

 Hemolytic anemia

5/56 (8.9%)

9/114 (7.9%)

0.776

1/29 (3.4%)

13/158 (8.2%)

0.606

 Pulmonary hypertension

3/56 (5.4%)

1/114 (0.9%)

0.105

1/29 (3.4%)

4/158 (2.5%)

1.000

 Myocardial involvement

0/56 (0)

0/114 (0)

NA

0/29 (0)

3/158 (1.9%)

1.000

 ILD

2/56 (3.6%)

1/114 (0.9%)

0.253

0/29 (0)

6/158 (3.8%)

0.622

 Alveolar hemorrhage

0/56 (0)

0/114 (0)

NA

0/29 (0)

0/29 (0)

NA

 Smooth muscle involvement

0/56 (0)

6/114 (5.3%)

0.179

0/29 (0)

5/158 (3.2%)

0.730

 Polyserositis

2/56 (3.6%)

6/114 (5.3%)

1.000

1/29 (3.4%)

7/158 (4.4%)

1.000

 APS

2/56 (3.6%)

5/114 (4.4%)

1.000

1/29 (3.4%)

4/158 (2.5%)

1.000

 TTP or TMA

0/56 (0)

0/114 (0)

NA

0/29 (0)

0/29 (0)

NA

 Secondary SS

5/56 (8.9%)

14/114 (12.3%)

0.611

3/29 (10.3%)

22/158 (13.9%)

0.823

  1. aThe period from the time they reached the SACQ/SQCQ to the time of recurrence (flare group) or at the end of follow-up (non-flare group)
  2. bThe period from the onset of SLE to the time they reached SACQ
  3. cCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent